Numinus Wellness (TSXV:NUMI) (OTCPK:LKYSF) is a leading psychedelics-focused mental healthcare company. The company’s mission is to help people heal and maintain wellness via the development and delivery of innovative mental health care, while also providing access to safe and secure, evidence-based psychedelic-assisted therapies. At Numinus Wellness, their model includes psychedelic production, research, and clinic care as these are three core factors at the forefront of healing symptoms for depression, anxiety, trauma, pain, and substance use. Furthermore, Numinus hopes to lead the integration of psychedelic-assisted therapies into mainstream clinical practice to achieve a healthier society.
Leading Psychedelic-Assisted Therapies and Research On The Rise
In November 2021, Numinus Wellness (TSXV:NUMI) (OTCPK:LKYSF) announced that it has secured two new Canadian psychedelic clinics, which will host the Canadian sites of the MAPS Public Benefit Corporation study namely, “A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX). To date, 25 Numinus-affiliated therapists have completed the MAPS’ training program so they can successfully deliver MDMA-assisted therapy. A large number of these therapists will also play a role in the upcoming trial.
“We are honored to host the Canadian sites of the MAPPUSX trial as we continue to examine the important findings around MDMA-assisted therapy for PTSD,” said Dr.Joe Flanders, VP of Psychology at Numinus and therapist at the Montreal site of the trial. “Our clinical and research teams are well positioned to implement MAPS’ research and, ultimately, to work with MAPS on the translation of research findings into mainstream clinical practice. We are excited about this study in both BC and Quebec and look forward to how the MAPPSUX study supports expanded collaboration in the future.”
In addition to managing the two new clinics, which are fully compliant with Health Canada regulations and ready to provide MDMA-assisted therapy, Numinus will host the Montreal and Vancouver sites in MAPPUSX to continue studying the safety and efficacy of MDMA in treating severe PTSD. The company will also financially support costs relating to therapists who deliver the therapeutic intervention in Numinus clinics during the trial.
The MAPPUSX study follows the previously completed multi-site phase 3 study of MDMA-assisted psychotherapy for PTSD (MAPP1), which revealed that 88% of participants experienced a clinically meaningful reduction in symptoms, while 67% no longer qualified for a PTSD diagnosis. The highly statistically significant results and excellent safety record suggest MDMA-assisted therapy will be an effective treatment for severe, chronic PTSD.
In October 2021, Numinus Wellness (TSXV:NUMI) (OTCPK:LKYSF) announced the expansion of its psychedelics research facility via an additional lab and application for federal licensing. This will broaden services so industry research and production can continue to prosper while also adding new revenue flow. Numinus Bioscience, the company’s research vertical, has submitted its request to Health Canada to obtain its second Dealer’s License. The expansion of the facility is expected to double the size of Numinus’ research footprint and is projected for completion in Summer 2022.
Earlier this Fall, Numinus Wellness (TSXV:NUMI) (OTCPK:LKYSF) also shared news of its acquisition of the Neurology Centre of Toronto, a well known Canadian provider of clinical neurologic care. The purchase agreement was initially announced in July 2021 but the company confirmed the closure of the deal in September 2021.
For more information on Numinus Wellness, visit the company website.
Author Shaan Powar 
